Treatment with intravesical oxybutynin chloride for neurogenic bladder in children

Abstract

 Clean intermittent catheterization in combination with oral anticholinergic agents (oxybutynin chloride) is the present standard therapy for children with neurogenic bladder dysfunction and detrusor overactivity. The mechanism of action of oxybutynin chloride involves its antimuscarinic properties that relax bladder smooth muscle. However, well-known complications arising from systemic anticholinergic effects may interfere with clinical use. When these side effects supersede therapeutic efficacy or this therapy fails to decrease bladder pressure to levels that protect the upper urinary tract, more invasive options are used, such as augmentation cystoplasty. We report here our experience with the intravesical oxybutynin chloride for neurogenic bladder in children.